Edgewise Therapeutics (EWTX) Competitors $14.35 -0.30 (-2.05%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$14.36 +0.01 (+0.07%) As of 08/29/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EWTX vs. RNA, AXSM, ABVX, NUVL, MRUS, CRSP, TGTX, CYTK, AAPG, and KRYSShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), Abivax (ABVX), Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), Ascentage Pharma Group International (AAPG), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Its Competitors Avidity Biosciences Axsome Therapeutics Abivax Nuvalent Merus CRISPR Therapeutics TG Therapeutics Cytokinetics Ascentage Pharma Group International Krystal Biotech Avidity Biosciences (NASDAQ:RNA) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk. Does the media refer more to RNA or EWTX? In the previous week, Avidity Biosciences had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 9 mentions for Avidity Biosciences and 8 mentions for Edgewise Therapeutics. Avidity Biosciences' average media sentiment score of 1.16 beat Edgewise Therapeutics' score of 1.06 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, RNA or EWTX? Avidity Biosciences has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Which has higher earnings and valuation, RNA or EWTX? Edgewise Therapeutics has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.73M558.55-$322.30M-$3.56-13.08Edgewise TherapeuticsN/AN/A-$133.81M-$1.55-9.26 Do analysts rate RNA or EWTX? Avidity Biosciences presently has a consensus target price of $67.00, suggesting a potential upside of 43.84%. Edgewise Therapeutics has a consensus target price of $40.55, suggesting a potential upside of 182.55%. Given Edgewise Therapeutics' higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.06Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91 Is RNA or EWTX more profitable? Edgewise Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -4,247.77%. Edgewise Therapeutics' return on equity of -30.65% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-4,247.77% -33.45% -30.22% Edgewise Therapeutics N/A -30.65%-29.18% SummaryEdgewise Therapeutics beats Avidity Biosciences on 7 of the 13 factors compared between the two stocks. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.54B$3.06B$5.66B$9.84BDividend YieldN/A2.28%3.93%4.04%P/E Ratio-9.2620.9283.2726.61Price / SalesN/A200.54451.26176.28Price / CashN/A44.0537.7059.65Price / Book2.578.0710.556.59Net Income-$133.81M-$53.98M$3.27B$266.12M7 Day Performance-3.37%-0.88%0.42%0.17%1 Month Performance0.84%6.20%5.91%3.02%1 Year Performance-23.47%7.13%48.11%19.69% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics2.3285 of 5 stars$14.35-2.0%$40.55+182.5%-22.1%$1.54BN/A-9.2660Positive NewsInsider TradeRNAAvidity Biosciences3.0789 of 5 stars$45.27-2.3%$67.00+48.0%+9.2%$5.96B$10.90M-12.72190Positive NewsInsider TradeAXSMAxsome Therapeutics4.7375 of 5 stars$116.31-1.9%$178.00+53.0%+36.1%$5.91B$385.69M-22.94380News CoveragePositive NewsInsider TradeABVXAbivax2.6177 of 5 stars$77.46+0.2%$92.33+19.2%+538.0%$5.85BN/A0.0061News CoveragePositive NewsAnalyst RevisionNUVLNuvalent3.3909 of 5 stars$74.05-2.7%$118.91+60.6%-10.4%$5.49BN/A-15.1140News CoveragePositive NewsMRUSMerus2.0969 of 5 stars$65.74-2.6%$88.64+34.8%+30.4%$5.10B$36.13M-11.9537News CoveragePositive NewsCRSPCRISPR Therapeutics3.716 of 5 stars$54.13-0.3%$71.60+32.3%+9.0%$4.94B$37.31M-9.97460Trending NewsAnalyst UpgradeAnalyst RevisionTGTXTG Therapeutics4.6531 of 5 stars$28.53-3.1%$46.25+62.1%+24.8%$4.67B$329M77.11290Positive NewsCYTKCytokinetics3.699 of 5 stars$37.01-3.5%$71.58+93.4%-38.4%$4.59B$85.74M-7.26250News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600Gap UpHigh Trading VolumeKRYSKrystal Biotech4.7659 of 5 stars$146.77-2.5%$210.38+43.3%-24.3%$4.36B$290.52M29.83210 Related Companies and Tools Related Companies Avidity Biosciences Competitors Axsome Therapeutics Competitors Abivax Competitors Nuvalent Competitors Merus Competitors CRISPR Therapeutics Competitors TG Therapeutics Competitors Cytokinetics Competitors Ascentage Pharma Group International Competitors Krystal Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
